Return to Statistics Toolbox

Random Forest analysis for Study ST003657

(Analysis AN006007 )

Select one or more experimental factors for Groups 1 and 2. The members of each group should be DIFFERENT.
Group1Experimental factorGroup2
Sample source:U251 | Condition:anti-GLS1 siRNA | Method of exposure:Transfection
Sample source:U251 | Condition:Control | Method of exposure:Direct exposure
Sample source:U251 | Condition:Control | Method of exposure:Transfection
Sample source:U251 | Condition:Control | Method of exposure:Transwell b.End3
Sample source:U251 | Condition:Control | Method of exposure:Transwell b.End3 + iNHA
Sample source:U251 | Condition:Lipofectamine | Method of exposure:Transfection
Sample source:U251 | Condition:PUREG4-LA12-anti-GLS1 siRNA | Method of exposure:Direct exposure
Sample source:U251 | Condition:PUREG4-LA12-anti-GLS1 siRNA | Method of exposure:Transwell b.End3
Sample source:U251 | Condition:PUREG4-LA12-anti-GLS1 siRNA | Method of exposure:Transwell b.End3 + iNHA
Sample source:U251 | Condition:PUREG4-LA12 | Method of exposure:Direct exposure
Sample source:U251 | Condition:PUREG4-LA12 | Method of exposure:Transwell b.End3
Sample source:U251 | Condition:PUREG4-LA12 | Method of exposure:Transwell b.End3 + iNHA
Sample source:U-87MG | Condition:anti-GLS1 siRNA | Method of exposure:Transfection
Sample source:U-87MG | Condition:Control | Method of exposure:Direct exposure
Sample source:U-87MG | Condition:Control | Method of exposure:Transfection
Sample source:U-87MG | Condition:Control | Method of exposure:Transwell b.End3
Sample source:U-87MG | Condition:Control | Method of exposure:Transwell b.End3 + iNHA
Sample source:U-87MG | Condition:Lipofectamine | Method of exposure:Transfection
Sample source:U-87MG | Condition:PUREG4-LA12-anti-GLS1 siRNA | Method of exposure:Direct exposure
Sample source:U-87MG | Condition:PUREG4-LA12-anti-GLS1 siRNA | Method of exposure:Transwell b.End3
Sample source:U-87MG | Condition:PUREG4-LA12-anti-GLS1 siRNA | Method of exposure:Transwell b.End3 + iNHA
Sample source:U-87MG | Condition:PUREG4-LA12 | Method of exposure:Direct exposure
Sample source:U-87MG | Condition:PUREG4-LA12 | Method of exposure:Transwell b.End3
Sample source:U-87MG | Condition:PUREG4-LA12 | Method of exposure:Transwell b.End3 + iNHA

  logo